Neoplasia/BPH

	The use of biparametric magnetic resonance imaging in active surveillance of prostate cancer. BJUI Compass Rivera López CA, Higgins MI, Jing Y, Alshak MN, Cheaib JG, Mamawala M, Landis P, Allaf ME, Macura KJ, Pavlovich CP. PMID: 42763568 [PubMed]
	External Validation and Comparison of Magnetic Resonance Imaging-based Risk Calculators for Detection of Clinically Significant Prostate Cancer: A Multi-institutional Study Incorporating Transrectal and Transperineal Biopsy Approaches. Eur Urol Focus Zlotta AR, Taborek A, Kwong JCC, Wang A, Boulakia N, Yin LB, Zhang KK, Nguyen DD, Srigley JR, der Kwast TV, Prendeville S, Booth R, Shahid A, Ringa M, Ali A, Diamond I, Bruni S, Klotz LH, Perlis N, Fleshner N, Finelli A, Diamand R, Ghai S, Haider M, Buckley R, Feifer A, Mian BM, Kulkarni GS. PMID: 42763233 [PubMed - as supplied by publisher]
	CRISPR and Gene Editing Approaches in Prostate Cancer: Clinical Applications and Therapeutic Potential. Crit Rev Oncol Hematol Patel V, Singh P, Dutta SP, Pande S, Langstang R, Kushwaha A. PMID: 42763006 [PubMed - as supplied by publisher]
	Application of a magnetic biosensor based on novel cracker-shaped noble metal nanoparticles in dual-modal multidimensional detection of bladder cancer urinary biomarker HAase. Biosens Bioelectron Li HZ, Zhu J, Weng GJ, Li JJ, Li L, Guo YB, Zhao JW. PMID: 42762645 [PubMed - as supplied by publisher]
	TAPESTRY study: impact of prior transurethral resection of the prostate on outcomes after robot-assisted radical prostatectomy: a propensity score-matched cohort study. J Robot Surg Lenart S, Zach J, Gutjahr G, Oberhammer L, Madersbacher S, Ponholzer A, Mikulits C, Banner A. PMID: 42762391 [PubMed - indexed for MEDLINE]
	Role of cytoreductive nephrectomy in metastatic medullary renal cell carcinoma: controlled analysis. World J Urol Le QC, Marmiroli A, Longoni M, Falkenbach F, Catanzaro C, Nicolazzini M, Polverino F, Goyal JA, Saad F, Schiavina R, Carmignani LF, Briganti A, Longo N, Graefen M, Palumbo C, Siech C, Banek S, Traumann M, Chun FK, Karakiewicz PI. PMID: 42762265 [PubMed - indexed for MEDLINE]
	Impact of one-year soy protein supplementation on serum metabolomic profiles: results from a randomized, placebo-controlled trial in prostate cancer patients. Nutr Food Sci Kato I, Emani SSB, Xu R, Yin X, Zhang X, Bosland MC, Kim S. PMID: 42762034 [PubMed]
	Development and external validation of a simple pre-biopsy risk stratification model for clinically significant prostate cancer in men with PI-RADS 3 lesions: a multicenter transperineal biopsy study. Front Oncol Peng X, Yi X, Tang S. PMID: 42761094 [PubMed]
	Metabolites from blood and formalin-fixed, paraffin-embedded tissue from participants with low- and high-grade prostate cancer: a pilot study. Front Oncol Graff RE, Bengtsson HL, Suh JH, Olshen AB, Wang EY, Allen RM, Van Blarigan EL, Kenfield SA, Cowan JE, Carroll PR, Simko J, Chan JM. PMID: 42761007 [PubMed]
	From hematuria warning to precision immunotherapy: an AI-assisted cross-platform analysis of bladder cancer information on social media. Front Med (Lausanne) Han P, Yang X, Li Q, Lu P, Wang P, Deng Z, Gui Z, Zong Y, Liu M. PMID: 42760942 [PubMed]
	Association between serum uric acid and benign prostatic hyperplasia among Chinese men aged 45 years or older: A prospective cohort study. Medicine (Baltimore) Li J, Cao P, Chen Y. PMID: 42760739 [PubMed - indexed for MEDLINE]
	Clinical efficacy of AI-navigated transperineal MRI-TRUS fusion biopsy for prostate cancer diagnosis: A retrospective cohort study. Medicine (Baltimore) Chen J, Xu Q, Li C, Zhang J. PMID: 42760671 [PubMed - indexed for MEDLINE]
	Single-cell transcriptomics combined with Mendelian randomization reveals the pivotal role of WDR83OS in clear cell renal cell carcinoma: An observational and bioinformatic study. Medicine (Baltimore) Xiao L, Yusan A, Cao Y, Yue F, Feng J, Wu H, Sun L, Qiu J, Xiao Y, Zhang S. PMID: 42760660 [PubMed - indexed for MEDLINE]
	Satisfaction with treatment decision-making and long-term experiences of life-prolonging treatments for metastatic castration-resistant prostate cancer. BMC Palliat Care Routier Cañigueral P, Wennman-Larsen A, Doveson S, Rönningås U, Holm M. PMID: 42760521 [PubMed - indexed for MEDLINE]
	Current status and future directions of AI in prostate cancer detection on MRI: a special report from the ESUR prostate MRI working group authors. Eur Radiol Cuocolo R, Ponsiglione A, Agrotis G, Barrett T, Brembilla G, Caglic I, Fali, Hamm CA, Messina E, Penzkofer T, Renard-Penna R, Rouvière O, Russo L, Sala E, Uhlig J, Padhani AR, de Rooij M, ESUR Prostate MRI Working Group. PMID: 42760428 [PubMed - as supplied by publisher]
	Assessment of Bone Metastases, Skeletal-Related Events and Bone-Targeting Agents in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line Systemic Therapy (Meet-URO 33 Study Subanalysis). Clin Genitourin Cancer Valsecchi AA, Rebuzzi SE, Cursano MC, Pantano F, Berardi R, Bimbatti D, Bonomi L, Bozza G, Bronte E, Buti S, Carella C, Cavo A, Cocorocchio E, Volta AD, Deppieri FM, Di Marco A, Di Napoli M, Fanelli M, Fantinel E, Dri A, Filippi R, Fornarini G, Galli L, Guida A, Icardi M, La Russa F, Lolli C, Lombardo L, Maines F, Maiorano BA, Masini C, Messina C, Nasso C, Ortega C, Pierantoni F, Procopio G, Scagliarini S, Signori A, Sorarù M, Tondulli L, Verzoni E, Vignani F, Vitale MG, Zai S, Zucali PA, De Giorgi U, Santini D, Di Maio M. PMID: 42760246 [PubMed - as supplied by publisher]
	Is This the End of the Cisplatin Eligibility Era in Muscle-invasive Bladder Cancer? Letter in reference to: Matthew D. Galsky, BegoÃ±a P. Valderrama, Marco Maruzzo, et al. Enfortumab vedotin and pembrolizumab in cisplatin-eligible bladder cancer. N Engl J Med 2026;395:338-48. doi:10.1056/NEJMoa2601486; and Galsky MD, Hahn NM, Rosenberg J, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol 2011;12:211-214. doi:10.1016/S1470-2045(10)70275-8. Eur Urol Giannatempo P, Cerbone L, Calabrò F. PMID: 42760245 [PubMed - as supplied by publisher]
	Can early (68)Ga-PSMA-11 PET/CT predict 6-month disease control in patients receiving first-line systemic therapy for metastatic clear-cell renal cell carcinoma? Protocol for the multicentre prospective phase II PSMA-RENAL study in Belgium. BMJ Open Seront E, Lhommel R, Van Maanen A, Pasoglou V, Gizzi M, Grisay G, Tombal B. PMID: 42760067 [PubMed - indexed for MEDLINE]
	The PART randomised trial protocol: Partial Ablation versus Radical Treatment for prostate cancer. BJU Int Bryant RJ, Leslie T, Laniado M, Sharma A, Grey A, Withington J, Blick C, Streeter E, Kotwal S, Hulson O, Cross W, Good DW, Omer A, Shah TT, Bedi N, Stroman L, Moore C, Sooriakumaran P, Ahmed HU, Brewster SF, Barber VS, Hewitt A, Calvert C, Scaife J, Shepherd D, Landeiro F, Wolstenholme J, Camilleri P, Verrill C, Lovell S, Pirkl M, Gleeson F, Williams R, Cook J, Holt CR, Hill M, Cook J, Radford J, Marian IR, Macpherson R, Elliott D, Donovan JL, Hamdy FC. PMID: 42760023 [PubMed - as supplied by publisher]
	Plasma cfDNA fragmentomics enables non-invasive detection and preoperative risk stratification of bladder cancer in a multicenter study. Cancer Lett Liu K, Bao H, Li G, Ran W, Yang P, Zhang Z, Li W, Li N, Ren M, Ding T, He P, Yang S, Hong X, Wang K, Xing X. PMID: 42759922 [PubMed - as supplied by publisher]

Articles 1 - 20 / 191410

Page 1 of 9571



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy